Title CALGB 100701) Phase II Study of Reduced-Intensity Allogeneic Stem Cell Transplant For High-Risk Chronic Lymphocytic Leukemia (CLL)
Principal Investigator Philip McCarthy, MD
Study Number 179210
Summary The purpose of the study is to determine if this treatment can improve 2-year current progression-free survival (PFS) in the early-disease cohort compared to historical controls. Specifically, we plan to study whether we can achieve 2-year PFS greater than or equal to 70% and to exclude 2-year PFS less than or equal to 50%.
See Clinicaltrials.gov link for current eligibility criteria.